Genmab — April 2020

[kkjoel]

GB, you've got it all

[Stockwatch1]

CS - Lidt uddybning af blue sky: Our Blue Sky scenario gives a valuation of DKK2460. Our Blue Sky scenario is based on stronger sales of Darzalex (USD 10bn in 2025), and ofatumumab (USD 5.1bn in 2025) and 100% pipeline success.

[Bulder]

4.5 mia $ for ofa i rms i 2025 er vist pænt over konsensus. Lå det ikke omkring 1 mia?

[E_L]

ok, they appear to put hardly any value in the pipeline for the 1950 valuation, with NPV of unpartnered products at DKK35/share

[E_L]

so one would imagine a CD3/CD20 deal at reasonable terms would imediately get them to raise target

[kkjoel]

GB, er HSBCs kursmål 930 OG en "reducer" anbefaling? (eller reducerede de deres kurmål..)

[Solsen]

10% of $4,5bn is a lot

[GeorgeBest]

kkjoel 11:48. HSBCs anbefaling er reducer - med kursmål 930

[DevOp]

Ja, HSBC må jo have vurderet upside-risikoen grundigt.. bob bob...

[DevOp]

Dara SC godkendelse, Ofa godkendelse og partneraftale i nævnte rækkefølge, så kan de vist bare sætte et "1" foran.

[E_L]

next week we'll get the ASCO Abstract Titles Released and then May 6 we may get some insight from Jan on any Corona impact on Dara sales?

[StockBull]

Genmab ser sku stærk ud og mon ikke en partnerdeal forhåbentligt inden udgang af Q2 får kursen i ny ATH. P.t oppe med ca. 8% for 2020

[GeorgeBest]

Jan mener partnerdeal kan være på plads omkring halvårsskiftet på trods af corona. Iflg. Stockwatch1 kl. 11.33 så mener Credit Suisse den kommer i andet halvår

[kkjoel]

juni, juli - tomato, tomaato

[Bulder]

Mon ikke Winkel kommer det lidt nærmere om et par uger?

[Bulder]

Bliver der forresten q&a igen, Helge?

[E_L]

re Tepezza (teprotumumab) : IGF-1R drugs travel from cancer cradle to Graves’ https://www.nature.com/articles/s41587-020-0481-8

[E_L]

“I’ve had patients crying and hugging me” after receiving Tepezza, adds Wester, who was involved in the drug’s clinical testing. “For those patients who have a good response, it’s really life-altering for them.”

[E_L]

In hopes of expanding the drug’s label, Horizon will soon launch an exploratory study in patients with diffuse cutaneous scleroderma, an autoimmune disorder in which excess collagen production causes skin thickening over large swathes of the body

[E_L]

“we see the scleroderma initial study as something that gives us insight into fibrotic diseases more broadly.”